When it comes to coordinating patient support services, Interconnect delivers

Your patient’s dedicated Care Manager team will help with the process from enrollment and start of treatment through ongoing treatment. Care Managers communicate with you and your staff, your patient, and the specialty pharmacy to help keep things running smoothly.

Interconnect is committed to reducing financial barriers to patients accessing their prescribed treatment, including providing assistance identifying and evaluating the potential options based on your patient’s insurance plan and eligibility.

  • Commercial insurance

    Qualified patients with commercial insurance may be eligible for the Interconnect Savings Program, which offers copay assistance where patients may be able to pay as little as $0.ª

  • Medicare/Medicaid

    Interconnect may provide information on financial support options, including the Patient Assistance Program for eligible patients who cannot afford their out-of-pocket costs, as well as options from independent charitable foundation programs.b

  • No insurance
    or underinsured for an Alfasigma therapy

    Qualified patients may be provided with access to their Alfasigma treatment at no cost under the Patient Assistance Program.

  • Limited Drug Program

    Quick Start Program: For NEW patients who have a recent denial or treatment delay.c

    Bridge Program: For EXISTING patients who
    have a recent denial or treatment delay.c

ªOffer not valid for patients enrolled in Medicare, Medicaid, VA, DoD, Tricare, or other federal or state healthcare programs. For program terms, conditions, and eligibility criteria, click here.
ᵇIndependent foundations are not associated with Alfasigma. Specific details and eligibility requirements can be found directly at the foundations’ websites. Alfasigma does not endorse or guarantee reimbursement or support from any independent charitable organization.
ᶜFor eligible commercial patients.

You are now leaving Interconnect

Any information you provide after you leave this site and enter another site will be subject to the other website’s privacy policy and terms and conditions. Interconnect is not responsible for the use, security, or disclosure of any information you may provide to another site.

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.

Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.

Interconnect's website is being temporarily maintained and is no longer fully functional for enrollment purposes due to the withdrawal of OCALIVA.

Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.

For all other inquiries please contact: info@interceptpharma.com